Elektrofi, Inc.

UEI
FSALANWTU197
CAGE
7PML7
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
elektrofi.com
Founded
2016
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Grant awards

Grant subawards

Prime recipient Prime award Amount Awarded
Oregon Health & Science University Enhanced environments for psychophysical evaluation and training R01DC018166 $36,904
Oregon Health & Science University A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission R01AI154559 $54,779

Similar vendors

About the company

Elektrofi, Inc. is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs.

Elektrofi, Inc. was awarded one prime federal contract, a $1.5 million firm fixed price definitive contract by the Defense Health Agency (DHA) to support Phase II of DHA's Small Business Innovation Research (SBIR) program. The contract calls for Elektrofi to deliver its ultra-high concentration protein delivery formulation technology to rapidly deploy treatments for COVID-19 and future pandemics. Research will be conducted over a two-year period in Boston, Massachusetts. The contract has a total small business set aside designation and is scheduled to conclude in November 2023.

Elektrofi, Inc. has been awarded five federal grant sub-awards from the National Institutes of Health (NIH) and the National Science Foundation (NSF). All five sub-awards supported research related to monoclonal antibody delivery systems, with the prime grantees being Oregon Health & Science University and an unnamed university. The research focused on areas such as development of long-acting CCR5 monoclonal antibodies for HIV transmission and enhanced environments for psychophysical evaluation and training.

Quick answers

Is Elektrofi, Inc. registered in SAM.gov?

Elektrofi, Inc.'s SAM.gov registration expired on February 9, 2024.

What is Elektrofi, Inc.'s most recent federal award?

Elektrofi, Inc.'s most recent federal contract award is Mrdc contract DHA sbir sequential PH II covid-19 pivot proposal no. H2S-0017 titled ultra-high concentration protein… (W81XWH21C0079), from Medical Command (Army), on July 2, 2021.

On GovTribe

See Elektrofi, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors